Standard electrochemotherapy (ECT) is effective in many tumour types but is confined to the treatment of small superficial lesions. Variable electrode-geometry ECT (VEG-ECT) may overcome these limitations by using long freely-placeable electrodes. Patients with bulky or deep-seated soft-tissue malignancies not amenable to resection participated in a single-arm phase-2 study (ISRCTN.11667954) and received a single course of VEG-ECT with intravenous bleomycin (15,000 IU/m 2) and concomitant electric pulses applied through an adjustable electrode array. The primary outcome was radiologic complete response rate (CRR) per RECIST; secondary endpoints included feasibility, metabolic response, toxicity (CTCAE), local progression-free survival (LPFS) and patient perception (EQ-5D). During 2009-2014, we enrolled 30 patients with trunk/limb sarcomas, melanoma, Merkel-cell carcinoma, and colorectal/lung cancer. Median tumour size was 4.7 cm. Electrode probes were placed under US/TC guidance (28 and 2 patients, respectively). Median procedure duration was 80 minutes. Tumour coverage rate was 97% (29 of 30 patients). Perioperative side-effects were negligible; one patient experienced grade-3 ulceration and infection. One-month 18 F-FDG-SUV decreased by 86%; CRR was 63% (95% CI 44-79%). Local control was durable in 24 of 30 patients (two-year LPFS, 62%). Patients reported an improvement in "usual activities", "anxiety/depression", and "overall health" scores. VEG-ECT demonstrated encouraging antitumour activity in soft-tissue malignancies; a single course of treatment produced high and durable responses, with low complications. Soft tissue metastases are a frequent event in patients with metastatic melanoma or soft tissue sarcomas (STS) but can also arise in those with breast, lung, and colon cancer 1,2. Although surgical resection remains the first therapeutic option, locoregional therapies are increasingly being considered by the oncology team with either curative or palliative intent 3-5. Moreover, the introduction of new active systemic agents has revamped the interest in locoregional therapies and their possible integration into synergistic therapeutic strategies 6,7. Over the last decade, electrochemotherapy (ECT) has demonstrated efficacy across a great variety of superficial malignancies, including melanoma, breast, head and neck and gynecologic cancers 8. In ECT, targeted electric pulses are administered employing small, fixed-geometry electrodes to attain reversible cell membrane